All In Biotech

Drug Trial Radar · NCT06616194

A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

AN INTERVENTIONAL, EFFICACY, AND SAFETY, PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH AN OPEN-LABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 636 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

636

Planned (sponsor's estimate)

Start

Nov 15, 2024

Primary completion

Feb 26, 2030

Study completion Apr 22, 2031

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Sep 27, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about the effect of a study medicine called rimegepant in adolescents who have frequent migraine attacks. Rimegepant is a tablet that disintegrates when you put it on or under your tongue. The study will enroll participants who have headache for 15 days (or more) every month, of which 8 days (or more) of migraine every month, and each untreated attack lasts for an average of 4-72 hours In the 1st part of the study approximately half of the participants will receive a rimegepant tablet every other day, and approximately half of the participants will receive an inactive oral tablet (that looks the same as the rimegepant tablet) every other day. Participant experiences when they are taking the study medicine will be compared to when they are taking the inactive tablet. This will help to determine if the study medicine is safe and effective. The 1st phase of the study will last 3 months. In the 2nd part of the study all the participants who stay on study will receive rimegepant tablet every other day. This 2nd phase of the study will last 1 year. This will help determine if the study medicine is safe when taken for a long period. Those who will participate in both phases will have up to 19 visits at the study clinic, about one every 4 weeks (this may vary from 2 to 8 weeks interval during the study). Home health visits may occur as well. A health check and blood sample will be conducted at the study clinic visits. Participants will have to complete a daily diary to record the migraine attacks.

Conditions

  • Migraine

Interventions

  • RimegepantDrug

    Rimegepant 75 mg orally disintegrating tablets

  • PlaceboDrug

    Matching placebo oral disintegrating tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of migraine days per monthTime frame: 12 Weeks

Locations

102 sites in 12 countries. Site status is shown where the registry gives one.

  • Xenoscience Inc

    Phoenix, Arizona

  • Adult & Child Neurology Medical Associates

    Long Beach, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • Chicago Headache Center and Research Institute

    Chicago, Illinois

  • Chicago Headache Center and Research Institute

    Naperville, Illinois

  • New England Regional Headache Center

    Worcester, Massachusetts

  • Michigan Headache & Neurological Institute

    Ann Arbor, Michigan

  • Clinvest Headlands Llc

    Springfield, Missouri

  • Rutgers University

    New Brunswick, New Jersey

  • OnSite Clinical Solutions

    Charlotte, North Carolina

  • Duke Health Center Creekstone

    Durham, North Carolina

  • Duke Lenox Baker Children's

    Durham, North Carolina

  • Duke Children's Health Center

    Durham, North Carolina

  • Wake Forest University Baptist Medical Center ( WFUBMC )

    Winston-Salem, North Carolina

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • UPMC Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania

  • Avera Medical Group Pediatric Specialists

    Sioux Falls, South Dakota

  • Avera Research Institute - Sioux Falls

    Sioux Falls, South Dakota

  • Avera Medical Group Pediatrics - Dawley Farm

    Sioux Falls, South Dakota

  • Dell Children's Medical Center

    Austin, Texas

  • Headlands-EI Paso

    El Paso, Texas

  • The University of Texas Health Science Center at Houston

    Houston, Texas

  • Wasatch Clinical Research, LLC

    Salt Lake City, Utah

  • Granger Medical Holladay - Holladay Clinic

    Salt Lake City, Utah

  • Seattle Children's Hospital

    Seattle, Washington

  • University Of Alberta Hospital

    Edmonton, Alberta, Canada

  • Stollery Children's Hospital

    Edmonton, Alberta, Canada

  • CaRe Clinic

    Red Deer, Alberta, Canada

  • London Health Sciences Centre - Verspeeten Family Cancer Centre

    London, Ontario, Canada

  • Anhui Provincial Hospital

    Hefei, China

  • Shanghai Children's Hospital

    Shanghai, China

  • The Second Affiliated Hospital of Hebei Medical University

    Shijiazhuang, China

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • Guangzhou First People's Hospital

    Guangzhou, Guangdong, China

  • Jingzhou First People's Hospital

    Jingzhou, Hubei, China

  • Wuhan Children's Hospital

    Wuhan, Hubei, China

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China

Showing 40 of 102 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.